Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

Monday, Nov 17, 2025 7:17 am ET1min read

Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

Chardan Capital Raises SAB Biotherapeutics Buy Rating to $12 from $11.

Comments



Add a public comment...
No comments

No comments yet